TScan Therapeutics, Inc. (CIK: 0001783328) EDGAR, Information, Filings... CompaniesBIO.Com

TScan Therapeutics, Inc.

Mailing address
830 WINTER STREET, WALTHAM, Delaware, 02451
Phone
857-399-9500
State location
Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
SIC
2836 - (CF Office: Office of Life Sciences) BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Filings
N/A

TScan Therapeutics, Inc. (CIK: 0001783328) is an American company incorporated in the state of Massachusetts. Head office is located at 830 WINTER STREET, WALTHAM, Massachusetts, 02451. Work in the industry 2836 - (CF Office: Office of Life Sciences) BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES). TScan Therapeutics, Inc. is a public company and trade via Over-The-Counter (OTC).

Owner	Filings	Transaction Date	Type of Owner
Dworak Leiden	0001986012	Jul-21-2023	officer: Chief Accounting Officer
Nichols Weston	0001746376	May-31-2023	10 percent owner
Lynx1 Capital Management LP	0001910456	May-31-2023	10 percent owner
EcoR1 Capital, LLC	0001587114	May-26-2023	10 percent owner
Klencke Barbara	0001647647	Apr-06-2023	director
Barton Debora	0001936730	Jul-05-2022	officer: Chief Medical Officer
BAKER JULIAN	0001087939	May-10-2022	director, 10 percent owner
BAKER FELIX	0001087940	May-10-2022	director, 10 percent owner
BAKER BROS. ADVISORS LP	0001263508	May-10-2022	director, 10 percent owner
Baker Brothers Life Sciences LP	0001363364	May-10-2022	director, 10 percent owner
667, L.P.	0001551139	May-10-2022	director, 10 percent owner
Baker Bros. Advisors (GP) LLC	0001580575	May-10-2022	director, 10 percent owner
ZDRAVESKI ZORAN	0001741285	Sep-07-2021	officer: Chief Legal Officer
BARBERICH TIMOTHY J	0001120355	Jul-15-2021	director
SOUTHWELL DAVID P	0001251553	Jul-15-2021	director, officer: Chief Executive Officer
Westphal Christoph H	0001291961	Jul-15-2021	director, 10 percent owner
Biggar Stephen R	0001340380	Jul-15-2021	director
Dorton Katina	0001617541	Jul-15-2021	director
Harel Ittai	0001632710	Jul-15-2021	director
MacBeath Gavin	0001738082	Jul-15-2021	officer: Chief Scientific Officer
Desmarais William	0001860207	Jul-15-2021	officer: Chief Business Officer
Gruia Gabriela	0001860326	Jul-15-2021	director
Silver Brian M.	0001860597	Jul-15-2021	officer: Chief Financial Officer

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by TScan Therapeutics, Inc.

Filings	Format	Description	Filed/Effective	File/Film Number
10-Q	Document	Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0000950170-24-095066 (34 Act) Size: 5922 KB	Aug-12-2024	001-40603 241194751
8-K	Document	Current report filing Acc-no: 0000950170-24-095063 (34 Act) Size: 328 KB	Aug-12-2024	001-40603 241194726
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950170-24-073696 ( Act) Size: 5 KB	Jun-14-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950170-24-073695 ( Act) Size: 5 KB	Jun-14-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950170-24-073694 ( Act) Size: 5 KB	Jun-14-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950170-24-073693 ( Act) Size: 5 KB	Jun-14-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950170-24-073692 ( Act) Size: 7 KB	Jun-14-2024
3	Document	Initial statement of beneficial ownership of securities Acc-no: 0000950170-24-073670 ( Act) Size: 16 KB	Jun-14-2024
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950170-24-073658 ( Act) Size: 21 KB	Jun-14-2024
S-8	Document	Initial registration statement for securities to be offered to employees pursuant to employee benefit plans Acc-no: 0001193125-24-161589 (33 Act) Size: 68 KB	Jun-14-2024	333-280212 241044709
8-K	Document	Current report filing Acc-no: 0001193125-24-161151 (34 Act) Size: 318 KB	Jun-14-2024	001-40603 241043137
10-Q	Document	Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0000950170-24-058198 (34 Act) Size: 5384 KB	May-13-2024	001-40603 24936878
8-K	Document	Current report filing Acc-no: 0000950170-24-058194 (34 Act) Size: 335 KB	May-13-2024	001-40603 24936858
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0000950170-24-052872 ( Act) Size: 5 KB	May-03-2024
3	Document	Initial statement of beneficial ownership of securities Acc-no: 0000950170-24-052061 ( Act) Size: 13 KB	May-02-2024
ARS	Document	Annual report to security holders Acc-no: 0001193125-24-125141 (34 Act) Size: 1754 KB	Apr-30-2024	001-40603 24897410
DEFA14A	Document	Additional definitive proxy solicitation materials Acc-no: 0001193125-24-125079 (34 Act) Size: 725 KB	Apr-30-2024	001-40603 24897275
DEF 14A	Document	Definitive proxy statements Acc-no: 0001193125-24-125066 (34 Act) Size: 903 KB	Apr-30-2024	001-40603 24897177
SC 13G	Document	Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0000929638-24-001648 (34 Act) Size: 97 KB	Apr-29-2024	005-92700 24890496
SC 13D/A	Document	Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities Acc-no: 0001104659-24-050607 (34 Act) Size: 96 KB	Apr-23-2024	005-92700 24865144

Recent 20 filings. View all TScan Therapeutics, Inc. filings

Overall rating 5.0

Aug 22, 2022

Ryan Storey

Huge help thank you for your help .. y'all make it so much easier

Aug 22, 2022

Catherine

Thanks I look forward to using the product to improve my skin tone

Aug 22, 2022

Pelisari

young lad who new his job ansered questions and new what was best for me.

TScan Therapeutics, Inc. overview
TScan Therapeutics, Inc. job
TScan Therapeutics, Inc. stock
TScan Therapeutics, Inc. ownership
TScan Therapeutics, Inc. CEO
TScan Therapeutics, Inc. documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.